AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.20
+0.14 (+1.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.06
Open7.07
Bid7.00 x 800
Ask7.74 x 4000
Day's Range6.90 - 7.43
52 Week Range6.90 - 23.75
Volume1,059,636
Avg. Volume1,346,360
Market Cap322.533M
Beta1.13
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Achaogen to Host Investor Lunch Updating Investors on Commercial Strategy Post FDA Approval of Plazomicin on July 12th in New York City

    Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, will host a lunch updating investors on the market opportunities for plazomicin, including the treatment of serious bacterial infections due to MDR Enterobacteriaceae with perspectives from key opinion leaders Steven Burdette, M.D. and Joshua Rosenberg, M.D., on Thursday, July 12, from 12:00pm – 1:30pm Eastern Time in New York City. Achaogen management will present an update on the commercial strategy for ZEMDRITM(plazomicin), which recently received U.S. Food and Drug Administration (FDA) approval for treating adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.

  • How Much Upside Do Analysts See in ViewRay Stock?
    Market Realist13 days ago

    How Much Upside Do Analysts See in ViewRay Stock?

    ViewRay (VRAY) is focused on manufacturing and commercializing MRIdian, its magnetic resonance (or MR) image-guided radiation therapy system, which uses MRI and external beam radiation therapy to concurrently image and treat cancer patients. In February 2017, it received 510(k) clearance from the Food and Drug Administration (or FDA) to market MRIdian Linac. In July 2018, six of the total seven analysts covering ViewRay have given the stock a “buy” or higher rating, while one analyst has given it a “sell” rating.

  • Why Achaogen Stock Fell Steeply Yesterday
    Market Realist21 days ago

    Why Achaogen Stock Fell Steeply Yesterday

    Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options. As the first once-daily aminoglycoside therapy approved for cUTI , this drug is expected to target the unmet demand from patients suffering from certain multidrug-resistant Enterobacteriaceae. Achaogen estimates the annual inpatient market opportunity for Zemdri in the United States at around 450,000 patients. Despite this favorable news, Achaogen witnessed an almost 20% drop in its share price from $12.02 on June 25 to $9.59 on June 26.

  • ACCESSWIRE21 days ago

    Today’s Research Reports on Stocks to Watch: Achaogen and Avinger

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).

  • Why Hertz Global Holdings, Sibanye-Stillwater, and Achaogen Slumped Today
    Motley Fool22 days ago

    Why Hertz Global Holdings, Sibanye-Stillwater, and Achaogen Slumped Today

    Find out which of these stocks fell the most.

  • A Mixed-Bag Decision Causes Achaogen's 24% Tumble
    Motley Fool22 days ago

    A Mixed-Bag Decision Causes Achaogen's 24% Tumble

    The FDA gave the company a green light for one indication, but it rejected the use of its antibiotic in another.

  • Benzinga22 days ago

    FDA Approves Achaogen's Antibiotic For Urinary Tract Infection, But Issues CRL For Bloodstream Infections

    Achaogen Inc (NASDAQ: AKAO)'s tryst with the FDA regarding its anti-bacterial agent plazomicin, as expected, ended with a mixed outcome, just as the FDA panel issued a split verdict on it when it met in May. Achaogen announced Tuesday its Zemdri, the trade name for plazomicin, was greenlighted by the FDA for treating adults with complicated urinary tract infections including pyelonephritis, due to certain Enterobacteriaceae for which there's limited or no alternative treatment option.

  • MarketWatch22 days ago

    Achaogen stock slides 11% premarket after FDA declines to approve treatment for bloodstream infection

    Shares of biotech Achaogen Inc. slid 11% in premarket trade Tuesday, after the company said it received Complete Response Letter from the U.S. Food and Drug Administration for a study evaluating a treatment for bloodstream infection. "The company intends to meet with the FDA to determine whether there is a feasible resolution to address the CRL," it said in a statement. Achaogen said the FDA approved its Zemdri treatment for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.

  • GlobeNewswire22 days ago

    UPDATE -- ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

    ―ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae―. ―ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI―. ―ZEMDRI ...

  • Reuters22 days ago

    Achaogen's antibiotic gets FDA nod for urinary tract infections

    Achaogen Inc said on Tuesday U.S. health regulators cleared its antibiotic to treat adults with complicated urinary tract infections, but declined approval for treating bloodstream infections. The U.S. Food and Drug Administration cited lack of evidence of effectiveness of the drug, previously known as plazomicin, in a clinical study to treat bloodstream infections, the company said in a statement. "We see limited impact on future revenues if plazomicin’s label does not include (bloodstream infections)," Wedbush analyst Robert Driscoll said in an interview last week.

  • ACCESSWIRE22 days ago

    Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • GlobeNewswire22 days ago

    ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

    ―ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae―. ―ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI―. ―ZEMDRI ...

  • Options Traders Expect Huge Moves in Achaogen (AKAO) Stock
    Zacks23 days ago

    Options Traders Expect Huge Moves in Achaogen (AKAO) Stock

    Investors in Achaogen (AKAO) need to pay close attention to the stock based on moves in the options market lately.

  • Benzinga26 days ago

    Achaogen In The Spotlight Ahead of FDA Verdict On Plazomicin

    Achaogen Inc (NASDAQ: AKAO) shares have been rangebound between $10 and $14 since late last year, with a mixed FDA panel vote on its antibiotic treatment candidate plazomicin in early May stifling any potential rally. Plazomicin is Achaogen's lead product candidate. It is a semisynthetic aminoglycoside antibiotic being developed for infections due to multidrug-resistant Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae, or CRE.

  • Why Did Achaogen Inc’s’ (NASDAQ:AKAO) Insiders Buy Up More Shares?
    Simply Wall St.28 days ago

    Why Did Achaogen Inc’s’ (NASDAQ:AKAO) Insiders Buy Up More Shares?

    Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. Achaogen’s insiders have investedRead More...

  • GlobeNewswirelast month

    Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

    SOUTH SAN FRANCISCO, Calif., June 11, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today ...

  • ACCESSWIRE2 months ago

    Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).

  • GlobeNewswire2 months ago

    Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

    SOUTH SAN FRANCISCO, Calif., May 24, 2018-- Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant gram-negative infections, today announced ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AKAO earnings conference call or presentation 4-May-18 12:30pm GMT

    Q1 2018 Achaogen Inc Earnings Call

  • ACCESSWIRE2 months ago

    Blog Exposure - Lexicon Pharma’s New XERMELO(R) (Telotristat Ethyl) Data Published in Clinical Therapeutics

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LXRX as the Company's latest news hit the wire. On May 04, 2018, the Company announced that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase-3 TELESTAR study were published in March issue of Clinical Therapeutics. The publication provides the first report of the effects of XERMELO® on changes in weight in patients with neuroendocrine tumors (NETs) and carcinoid syndrome that participated in the Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome (TELESTAR) study.

  • Associated Press2 months ago

    Achaogen: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.06. Losses, adjusted for non-recurring costs and to extinguish debt, were 98 cents per share. The results ...

  • GlobeNewswire2 months ago

    Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update

    --FDA Advisory Committee voted in favor of plazomicin for treatment of adults with complicated urinary tract infections--. --Conference call today at 8:30 a.m. Eastern Time--. SOUTH SAN FRANCISCO, Calif., ...

  • ACCESSWIRE2 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. To listen ...

  • Benzinga2 months ago

    Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News

    Achaogen Inc (NASDAQ: AKAO) shares are tumbling Thursday after a mixed FDA panel vote on Plazomicin, its lead candidate to treat serious bacterial infections due to multidrug-resistant enterobacteriaceae. The FDA's Antimicrobial Drugs Advisory Committee voted 11-4 that the company failed to provide substantial evidence of safety and effectiveness of its plazomicin to treat bloodstream infections in patients with limited or no treatment options. The EPIC trial is evaluating the pipeline candidate for complicated UTIs, and is a single pivotal trial supporting a New Drug Application in the U.S. and Marketing Authorization Application, or MAA, in Europe.